Maxigen Biotech (TPE:1783) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1783 Maxigen Biotech Inc TPE:1783
87 GF Score
Price NT$40.30
GF Value NT$61.43
Valuation Significantly Undervalued
View Full Analysis

What is Maxigen Biotech Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

TPE:1783
87GF Score
Maxigen Biotech Inc TPE:1783
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Maxigen Biotech (TPE:1783) Overvalued in 2026?

Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued. The current stock price of NT$40.30 is trading 34.4% below its estimated GF Value™ of NT$61.43. GuruFocus considers Maxigen Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1783:

  • Dividends Received:
  • GF Value™: NT$61.43 vs. price of NT$40.30 (34.4% below fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Maxigen Biotech Business Description

Address No.88, Keji 1st Road, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score

Get the complete analysis for TPE:1783

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$40.30
Price
NT$61.43
GF Value